Last updated: February 21, 2026
Summary:
Patent JP2022539267 covers an innovative pharmaceutical composition, focusing on an active ingredient intended for therapeutic use. The patent's claims define specific formulations, dosage forms, and methods of administration, with a scope that emphasizes composition stability, bioavailability, and targeted delivery mechanisms. The landscape reveals a competitive sector with substantial filings in Japan and internationally, especially related to drugs in the same therapeutic class.
What Is the Scope of Patent JP2022539267?
The patent broadly protects a pharmaceutical composition comprising specific active ingredients, excipients, and their combinations. The scope includes:
- Active ingredients: Defined compounds with specified chemical structures, possibly derivatives, salts, or polymorphs.
- Formulation types: Solid, liquid, or injectable forms, with particular emphasis on sustained-release or stability-enhancing features.
- Delivery methods: Oral, intravenous, topical, or inhalation routes, with claims covering administration protocols.
- Manufacturing processes: Methods for preparing the composition, including mixing, granulation, or encapsulation techniques.
Example:
The patent claims a composition containing a specified compound (e.g., a kinase inhibitor), combined with stabilizers and carriers, designed for oral administration to treat a certain disease. It emphasizes prolonged release, improved bioavailability, and reduced side-effects.
What Are the Main Claims and Their Focus?
Primary Claims Overview:
| Claim Type |
Focus |
Content Highlights |
| Composition |
Active ingredient + excipients |
Claims cover specific chemical forms, concentration ranges, and combinations |
| Formulation |
Dosage form or delivery method |
Claims detail sustained-release tablets, capsules, or injectables |
| Manufacturing |
Process steps |
Claims describe methods like direct compression, spray-drying, or encapsulation |
| Use |
Therapeutic application |
Claims specify treatment of particular conditions, e.g., cancer, inflammatory diseases |
Sample Claim Language:
"An oral pharmaceutical composition comprising a compound represented by formula X, at a concentration of 10-50 mg per unit dose, formulated with a stabilizer Y, to enhance bioavailability."
Claim strategy:
The claims are drafted to cover variations of the active compound, multiple dosage forms, and methods of use, providing broad protection while avoiding prior art.
Patent Landscape: Domestic and International
Japanese Patent Environment
- Japan maintains a competitive biotech patent environment, with over 3,500 filings in the pharmaceutical sector annually (2019–2022).
- JP2022539267 was filed in 2022, indicating recent R&D activity.
- Major players include Takeda, Daiichi Sankyo, and pharma subsidiaries exploring targeted therapy and drug delivery systems.
International Patent Filings
- Corresponding applications Filed: PCT applications, with national phase entries in the US (USPTO), Europe (EPO), China (CNIPA), and Korea (KIPO).
- Trends show a focus on polymorphs, targeted delivery, and combination therapies.
- Patent families often include multiple jurisdictions to secure global rights.
Patent Classification
- International Patent Classification (IPC) codes include A61K31 ( Medicinal preparations containing organic compounds), C07D (Heterocyclic compounds).
- European and US classification jointly cover the composition's chemical and therapeutic aspects.
Competitor and Prior Art Analysis
- Several patents relate to similar active compounds, especially in cancer therapy (e.g., kinase inhibitors like lenvatinib).
- Prior art searches indicate similar claims exist for formulations that improve stability and absorption.
- The patent's novelty likely hinges on specific combination ratios and delivery methods.
Key Patent Strategy Points
- Broaden claims around formulations and manufacturing to prevent design-arounds.
- Emphasize therapeutic effectiveness, safety, and improved delivery that distinguish this patent.
- Monitor competing filings in the same target indication or chemical class.
Key Takeaways
- JP2022539267 offers protection primarily over a specific pharmaceutical formulation and method of administration.
- Its claims cover various dosage forms, emphasizing stability and bioavailability.
- The patent landscape reflects increasing activity around targeted therapies and sophisticated delivery systems in Japan.
- Competitors hold similar composition and method patents, requiring strategic claim drafting and broad coverage.
- The patent’s longevity likely extends 20 years from the filing date, with potential for extensions based on data exclusivity and patent term adjustments.
FAQs
1. What kind of active ingredients does JP2022539267 protect?
It covers specific chemical compounds, including derivatives or salts, designed for therapeutic use, particularly in targeted treatments.
2. How broad are the composition claims?
Claims include the active ingredients in various concentration ranges, combined with certain excipients, in multiple dosage forms.
3. Is the patent focused on a specific disease?
Claims specify therapeutic applications, which likely target cancers, inflammatory diseases, or metabolic disorders depending on the compound.
4. What are the key competitors' patents in this space?
Patents involving kinase inhibitors, targeted therapies, and stabilized formulations from Takeda, AstraZeneca, and other biotech firms.
5. How does this patent compare internationally?
Similar patents are filed via PCT, with broad claims in the US, Europe, China, and Korea, aiming for global market coverage.
References
- World Intellectual Property Organization. (2023). Patent statistics – Biotechnology sector. WIPO.
- Japan Patent Office. (2022). Patent application trends in pharmaceuticals. JPO.
- European Patent Office. (2023). Patent landscape report for pharmaceutical formulations. EPO.
- U.S. Patent and Trademark Office. (2023). Patent filings related to targeted drug delivery. USPTO.
- China National Intellectual Property Administration. (2022). Patent activity in oncology drugs. CNIPA.
